Nasdaq · Biotech stocks database

PBLS — Parabilis Medicines Inc.

PBLS (Parabilis Medicines Inc.) stock: $41.73, $5.09B market cap, $1.12B cash, $3.97B EV, $5.74B fully diluted market cap. Next expected readout: Apr-27. Lead program: FOG-001 (Cancer), Phase 2. Data from Fully Diluted's biotech stocks database.

Share price

$41.73

Market cap

$5,089.1M

Cash

$1,120.7M

Enterprise value

$3,974.8M

Balance sheet

Cash	$1,120.7M
Debt	$6.4M
Net cash	$1,114.3M
Enterprise value	$3,974.8M
Basic shares	121.9M shares
Fully diluted shares	137.7M shares
Fully diluted market cap	$5,744.7M
Cash per share	$9.19

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PBLS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
May 13 - Jun 24	FOG-001	Phase 2	Cancer; Colorectal Cancer; Solid Tumor	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	FOG-001
Lead indication	Cancer
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05919264	Phase 2	Recruiting	Sponsor	PBLS	—	Cancer; Colorectal Cancer; Solid Tumor	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Parabilis Medicines, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	1,920,805	+1,920,805	1.14%	2026-08-14
Logos Global Management	525,000	+525,000	0.62%	2026-08-14
Baker Bros. Advisors	500,000	+500,000	0.07%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego